AA
PDLI

ALPS Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

ALPS Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-145,354
Closed -$458K – 906
2020
Q3 		$458K Sell
145,354
-13,627
-9% -$43.5K 0.01% 469
2020
Q2 		$463K Sell
158,981
-48,617
-23% -$154K 0.01% 455
2020
Q1 		$585K Sell
207,598
-24,202
-10% -$78K 0.01% 418
2019
Q4 		$752K Buy
231,800
+4,118
+2% +$12K 0.01% 434
2019
Q3 		$492K Sell
227,682
-24,829
-10% -$66.4K ﹤0.01% 500
2019
Q2 		$793K Sell
252,511
-100,077
-28% -$325K 0.01% 379
2019
Q1 		$1.31M Buy
352,588
+15,222
+5% +$51.4K 0.01% 274
2018
Q4 		$978K Buy
337,366
+80,063
+31% +$220K 0.01% 308
2018
Q3 		$677K Sell
257,303
-109,922
-30% -$270K ﹤0.01% 485
2018
Q2 		$859K Buy
367,225
+4,631
+1% +$12.9K 0.01% 370
2018
Q1 		$1.07M Buy
362,594
+45,449
+14% +$124K 0.01% 301
2017
Q4 		$869K Sell
317,145
-143,801
-31% -$442K 0.01% 284
2017
Q3 		$1.56M Buy
460,946
+179,300
+64% +$499K 0.01% 204
2017
Q2 		$696K Buy
281,646
+25,472
+10% +$58.6K ﹤0.01% 295
2017
Q1 		$582K Buy
256,174
+30,956
+14% +$68.5K ﹤0.01% 294
2016
Q4 		$477K Sell
225,218
-13,833
-6% -$38.6K ﹤0.01% 443
2016
Q3 		$801K Sell
239,051
-129,043
-35% -$410K 0.01% 231
2016
Q2 		$1.16M Buy
368,094
+37,187
+11% +$124K 0.01% 203
2016
Q1 		$1.1M Buy
330,907
+22,464
+7% +$70K 0.01% 184
2015
Q4 		$1.09M Sell
308,443
-41,493
-12% -$174K 0.01% 215
2015
Q3 		$1.76M Buy
349,936
+114,217
+48% +$654K 0.02% 179
2015
Q2 		$1.52M Buy
235,719
+83,094
+54% +$557K 0.01% 184
2015
Q1 		$1.07M Buy
152,625
+86,043
+129% +$623K 0.01% 184
2014
Q4 		$513K Sell
66,582
-3,796
-5% -$30K ﹤0.01% 455
2014
Q3 		$526K Buy
70,378
+840
+1% +$7.8K ﹤0.01% 553
2014
Q2 		$673K Buy
69,538
+1,772
+3% +$15.8K 0.01% 235
2014
Q1 		$563K Buy
67,766
+7,196
+12% +$61.7K 0.01% 462
2013
Q4 		$551K Buy
60,570
+29,410
+94% +$248K 0.01% 275
2013
Q3 		$248K Buy
+31,160
New +$250K ﹤0.01% 480

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
HW
Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

ALPS Advisors's PDLI Position: Q4 2020 in Review

ALPS Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 145,354 shares — an estimated $458K sold.

ALPS Advisors first reported a position in PDLI in Q3 2013 and held it in 29 quarters. The position peaked at $1.76M in Q3 2015. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • ALPS Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • ALPS Advisors sold 145,354 PDL BioPharma, Inc. shares in Q4 2020, an estimated $458K.
  • ALPS Advisors first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 29 quarters.
  • ALPS Advisors's PDL BioPharma, Inc. position peaked at $1.76M in Q3 2015.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on ALPS Advisors's 13F filing for Q4 2020, filed 3 Feb 2021.